The record number of approvals shows the Agency's progress in terms of efficiency and commitment to generics and innovation policies.
Anvisa starts a new phase of the Online Optimized Analysis Project to speed up post-registration biological applications.
Anvisa (National Health Surveillance Agency) has released a guide containing crucial information for registering sunscreens.
In 2023, Anvisa (National Health Surveillance Agency) accelerated approvals, modernized regulations and increased regulatory publications.
The generic drugs policy, established in 1999, represented an important step forward for the country's public health.
ANVISA has announced the availability of the list of medicines that must submit Periodic Benefit-Risk Assessment Reports.
The covid-19 (recombinant) immunizing zika vaccine with s-protein and saponin-based adjuvant has been approved.
The document provides guidelines on monitoring adverse events in transplants, grafts and assisted human reproduction.
MAPA aims to boost national agribusiness, taking advantage of opportunities to promote Brazilian products on the market.
Anvisa has approved a gene therapy drug to treat hematologic cancer (gene therapy using patients' genetically modified T cells).